Aspiriant LLC’s Johnson & Johnson JNJ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.04M | Buy |
20,620
+754
| +4% | +$176K | 0.14% | 69 |
|
|
2025
Q4 | $4.11M | Buy |
19,866
+570
| +3% | +$113K | 0.12% | 79 |
|
|
2025
Q3 | $3.58M | Sell |
19,296
-930
| -5% | -$159K | 0.11% | 79 |
|
|
2025
Q2 | $3.09M | Sell |
20,226
-766
| -4% | -$118K | 0.1% | 84 |
|
|
2025
Q1 | $3.48M | Sell |
20,992
-1,368
| -6% | -$214K | 0.12% | 69 |
|
|
2024
Q4 | $3.23M | Sell |
22,360
-851
| -4% | -$132K | 0.12% | 74 |
|
|
2024
Q3 | $3.76M | Buy |
23,211
+2,085
| +10% | +$332K | 0.14% | 66 |
|
|
2024
Q2 | $3.09M | Sell |
21,126
-2,673
| -11% | -$398K | 0.13% | 73 |
|
|
2024
Q1 | $3.77M | Buy |
23,799
+821
| +4% | +$131K | 0.16% | 62 |
|
|
2023
Q4 | $3.6M | Buy |
22,978
+177
| +0.8% | +$27.1K | 0.16% | 61 |
|
|
2023
Q3 | $3.55M | Sell |
22,801
-224
| -1% | -$37K | 0.18% | 62 |
|
|
2023
Q2 | $3.81M | Sell |
23,025
-289
| -1% | -$46.6K | 0.19% | 59 |
|
|
2023
Q1 | $3.61M | Sell |
23,314
-1,201
| -5% | -$194K | 0.19% | 61 |
|
|
2022
Q4 | $4.33M | Buy |
24,515
+976
| +4% | +$169K | 0.22% | 54 |
|
|
2022
Q3 | $3.85M | Sell |
23,539
-320
| -1% | -$54.1K | 0.19% | 55 |
|
|
2022
Q2 | $4.23M | Sell |
23,859
-848
| -3% | -$151K | 0.2% | 56 |
|
|
2022
Q1 | $4.38M | Sell |
24,707
-751
| -3% | -$128K | 0.24% | 54 |
|
|
2021
Q4 | $4.36M | Buy |
25,458
+2,085
| +9% | +$341K | 0.23% | 54 |
|
|
2021
Q3 | $3.77M | Sell |
23,373
-396
| -2% | -$67.6K | 0.22% | 52 |
|
|
2021
Q2 | $3.92M | Sell |
23,769
-180
| -0.8% | -$29.8K | 0.22% | 47 |
|
|
2021
Q1 | $3.93M | Buy |
23,949
+175
| +0.7% | +$28.3K | 0.25% | 39 |
|
|
2020
Q4 | $3.74M | Sell |
23,774
-5,335
| -18% | -$787K | 0.26% | 41 |
|
|
2020
Q3 | $4.33M | Buy |
29,109
+4,313
| +17% | +$638K | 0.34% | 36 |
|
|
2020
Q2 | $3.49M | Sell |
24,796
-12,052
| -33% | -$1.76M | 0.32% | 39 |
|
|
2020
Q1 | $4.83M | Buy |
36,848
+13,477
| +58% | +$1.91M | 0.48% | 30 |
|
|
2019
Q4 | $3.41M | Sell |
23,371
-5,140
| -18% | -$697K | 0.32% | 40 |
|
|
2019
Q3 | $3.69M | Sell |
28,511
-12,397
| -30% | -$1.63M | 0.33% | 45 |
|
|
2019
Q2 | $5.69M | Sell |
40,908
-1,472
| -3% | -$204K | 0.47% | 40 |
|
|
2019
Q1 | $5.91M | Buy |
42,380
+8,689
| +26% | +$1.16M | 0.48% | 40 |
|
|
2018
Q4 | $4.35M | Sell |
33,691
-1,510
| -4% | -$211K | 0.33% | 50 |
|
|
2018
Q3 | $4.87M | Sell |
35,201
-11,567
| -25% | -$1.54M | 0.42% | 45 |
|
|
2018
Q2 | $5.67M | Sell |
46,768
-2,339
| -5% | -$292K | 0.49% | 41 |
|
|
2018
Q1 | $6.29M | Buy |
49,107
+31,892
| +185% | +$4.31M | 0.55% | 37 |
|
|
2017
Q4 | $2.4M | Sell |
17,215
-29,867
| -63% | -$4.16M | 0.71% | 27 |
|
|
2017
Q3 | $6.12M | Sell |
47,082
-3,953
| -8% | -$524K | 0.51% | 39 |
|
|
2017
Q2 | $6.75M | Sell |
51,035
-2,658
| -5% | -$339K | 0.59% | 35 |
|
|
2017
Q1 | $6.69M | Buy |
53,693
+8,097
| +18% | +$967K | 0.57% | 34 |
|
|
2016
Q4 | $5.25M | Sell |
45,596
-172
| -0.4% | -$19.9K | 0.48% | 32 |
|
|
2016
Q3 | $5.41M | Sell |
45,768
-11,776
| -20% | -$1.43M | 0.54% | 28 |
|
|
2016
Q2 | $5.69M | Buy |
57,544
+8,544
| +17% | +$971K | 0.54% | 30 |
|
|
2016
Q1 | $5.3M | Buy |
49,000
+44,967
| +1,115% | +$4.66M | 0.51% | 32 |
|
|
2015
Q4 | $414K | Buy |
4,033
+673
| +20% | +$67.7K | 0.05% | 63 |
|
|
2015
Q3 | $314K | Sell |
3,360
-2,914
| -46% | -$282K | 0.03% | 82 |
|
|
2015
Q2 | $611K | Buy |
6,274
+1,895
| +43% | +$190K | 0.06% | 64 |
|
|
2015
Q1 | $441K | Sell |
4,379
-1,731
| -28% | -$176K | 0.06% | 65 |
|
|
2014
Q4 | $639K | Buy |
6,110
+559
| +10% | +$58.9K | 0.09% | 54 |
|
|
2014
Q3 | $396K | Buy |
5,551
+1,616
| +41% | +$168K | 0.06% | 67 |
|
|
2014
Q2 | $412K | Buy |
3,935
+313
| +9% | +$31.6K | 0.06% | 69 |
|
|
2014
Q1 | $356K | Buy |
3,622
+1,134
| +46% | +$105K | 0.05% | 70 |
|
|
2013
Q4 | $228K | Buy |
+2,488
| New | +$229K | 0.04% | 69 |
|
Other funds holding JNJ
VCM
VPM
Aspiriant LLC's JNJ Position: Q1 2026 in Review
Aspiriant LLC increased its Johnson & Johnson (JNJ) stake by 3.8% in Q1 2026, buying an estimated $176K and bringing the position to 20,620 shares worth $5.04M. The position accounts for 0.14% of the portfolio, ranked #69.
Aspiriant LLC first reported a position in JNJ in Q4 2013 and has held it in 50 quarters since. The position peaked at $6.75M in Q2 2017. 4,613 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.
- Aspiriant LLC held 20,620 shares of Johnson & Johnson worth $5.04M as of Q1 2026.
- Aspiriant LLC bought 754 Johnson & Johnson shares in Q1 2026, an estimated $176K.
- Johnson & Johnson made up 0.14% of Aspiriant LLC's portfolio in Q1 2026, its #69 holding.
- Aspiriant LLC first reported a position in Johnson & Johnson in Q4 2013 and has held it in 50 quarters since.
- Aspiriant LLC's Johnson & Johnson position peaked at $6.75M in Q2 2017.
- 4,613 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.
Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.